INT158563

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 8
Disease Relevance 4.31
Pain Relevance 1.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Ctgf) cytosol (Ctgf) extracellular space (Ctgf)
extracellular region (Ctgf) Golgi apparatus (Ctgf) proteinaceous extracellular matrix (Ctgf)
Anatomy Link Frequency
PSC 1
Ctgf (Mus musculus)
Pain Link Frequency Relevance Heat
fibrosis 129 98.94 Very High Very High Very High
Pain 6 95.44 Very High Very High Very High
metalloproteinase 1 89.92 High High
Inflammation 45 89.12 High High
alcohol 2 78.52 Quite High
analgesia 1 76.80 Quite High
Chronic pancreatitis 1 61.00 Quite High
Analgesic 1 58.92 Quite High
Osteoarthritis 1 50.00 Quite Low
anesthesia 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Primary Sclerosing Cholangitis 7 99.60 Very High Very High Very High
Fibrosis 197 98.94 Very High Very High Very High
Pain 5 95.44 Very High Very High Very High
Blister 93 94.16 High High
INFLAMMATION 54 89.12 High High
Keloid Scars 61 87.92 High High
Ocular Hypertension 51 81.60 Quite High
Toxicity 9 78.00 Quite High
Disease 29 75.72 Quite High
Obesity 6 74.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CTGF and SPARC protein levels also were reduced by their corresponding siRNAs (P = 0.002 and 0.0004, respectively).


Negative_regulation (reduced) of CTGF
1) Confidence 0.56 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.39 Pain Relevance 0.13
Although down-regulation of CTGF has been employed in treating fibrotic conditions [28], application of SPARC inhibition in attenuation of a fibrotic process in a therapeutic animal model has not been reported.
Negative_regulation (regulation) of CTGF associated with fibrosis
2) Confidence 0.41 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.49 Pain Relevance 0.05
In the presence of 4MP, DAS, or the anti-oxidants vitamin D or catalase, there was a substantial decrease in the ability of ethanol to stimulate CCN2 mRNA expression and a concomitant decrease in CCN2-positive PSC.
Negative_regulation (decrease) of CCN2 in PSC associated with primary sclerosing cholangitis
3) Confidence 0.37 Published 2009 Journal Growth Factors Section Abstract Doc Link 19280452 Disease Relevance 0.72 Pain Relevance 0.19
pathway [22-25], and inhibition of Ctgf reduced expression of the fibrotic effect of TGF-?
Negative_regulation (inhibition) of Ctgf associated with fibrosis
4) Confidence 0.36 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2888211 Disease Relevance 0.10 Pain Relevance 0
Suppression of pSmad2, CTGF, and ?
Negative_regulation (Suppression) of CTGF
5) Confidence 0.26 Published 2010 Journal Molecular Vision Section Abstract Doc Link PMC2956700 Disease Relevance 0.71 Pain Relevance 0
Meanwhile, suppression of CTGF and ?
Negative_regulation (suppression) of CTGF
6) Confidence 0.26 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2956700 Disease Relevance 0.63 Pain Relevance 0.04
The reduction in fibrosis seen with the IA HA injections was not reflected in reduced CTGF levels, suggesting alternate mechanisms for the anti-fibrotic effect.
Negative_regulation (reduced) of CTGF associated with fibrosis
7) Confidence 0.23 Published 2008 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2468886 Disease Relevance 0.95 Pain Relevance 0.70
M, and the reduction of CTGF and ?
Negative_regulation (reduction) of CTGF
8) Confidence 0.22 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2956700 Disease Relevance 0.33 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox